The FDA requires generic drug labels to match brand-name labels exactly, except for manufacturer details. This ensures safety but creates dangerous delays in updating critical warnings. Learn what's mandated, why it matters, and how it's changing.
Side effects are the #1 reason people stop taking their medications-even when they know it’s important. Learn how to talk to your pharmacist, adjust your plan, and stay on track without suffering in silence.
Metronidazole can cause serious nerve damage leading to numbness and tingling, especially after 42 grams total. Learn the signs, when to stop the drug, and how to prevent permanent injury.
Prescribers remain cautious about substituting generic versions of narrow therapeutic index (NTI) drugs due to risks of therapeutic failure or toxicity. Despite FDA assurances, doctors, pharmacists, and patients report real-world concerns that influence prescribing and dispensing practices.
Bioequivalence testing for combination products like FDCs, topical creams, and inhalers faces unique scientific and regulatory hurdles. Learn why these generics take longer, cost more, and often fail approval - and what’s being done to fix it.
Learn how to successfully appeal a denied medication prior authorization. Step-by-step guide with real data on success rates, required documents, insurer rules, and how to get your doctor's help.
The FDA now conducts unannounced inspections of overseas food facilities to ensure imported products meet U.S. safety standards. Learn how risk-based targeting, legal consequences, and new policies are reshaping global food safety.
The FDA uses Import Alerts to block drugs from non-compliant manufacturers, especially targeting unsafe GLP-1 APIs. Learn how the Green, Yellow, and Red system works, who's affected, and what it means for global pharma supply chains.
Medicaid generics cut prescription costs by up to 90% for low-income patients, with average copays of just $6.16 compared to $56.12 for brand-name drugs. Learn how rebates, PBMs, and state policies affect access and savings.
Digoxin generics may meet FDA bioequivalence standards, but switching between brands can cause dangerous shifts in blood levels. Learn why strict monitoring and consistency matter for this narrow therapeutic index drug.
